|
1
|
Ho JH: An epidemiologic and clinical study
of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys.
4:182–198. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McDermott AL, Dutt SN and Watkinson JC:
The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied
Sci. 26:82–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng Z, Xu S, Liu M, Zeng YX and Kang T:
Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal
carcinoma cells to radiotherapy and chemotherapy in vitro and in
vivo. Cancer Lett. 297:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK,
Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and
Ensley JF: Chemoradiotherapy versus radiotherapy in patients with
advanced nasopharyngeal cancer: Phase III randomized Intergroup
study 0099. J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
|
|
6
|
Portugal J, Bataller M and Mansilla S:
Cell death pathways in response to antitumor therapy. Tumori.
95:409–421. 2009.PubMed/NCBI
|
|
7
|
Wang X, Masters JR, Wong YC, Lo AK and
Tsao SW: Mechanism of differential sensitivity to cisplatin in
nasopharyngeal carcinoma cells. Anticancer Res. 21:403–408.
2001.PubMed/NCBI
|
|
8
|
Cheung HW, Jin DY, Ling MT, Wong YC, Wang
Q, Tsao SW and Wang X: Mitotic arrest deficient 2 expression
induces chemosensitization to a DNA-damaging agent, cisplatin, in
nasopharyngeal carcinoma cells. Cancer Res. 65:1450–1458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shannon KM: Resistance in the land of
molecular cancer therapeutics. Cancer Cell. 2:99–102. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y,
Huang Q, Jiang L, Huang W, Cheng W and Liu Z: Establishment and
characterization of multi-drug resistant, prostate
carcinoma-initiating stem-like cells from human prostate cancer
cell lines 22RV1. Mol Cell Biochem. 340:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao
F, Chen L, Xiao GG, Molnár J and Wang Q: Down-regulation of
P-glycoprotein is associated with resistance to cisplatin and VP-16
in human lung cancer cell lines. Anticancer Res. 30:3593–3598.
2010.PubMed/NCBI
|
|
12
|
Peng X, Li W and Tan G: Reversal of taxol
resistance by cisplatin in nasopharyngeal carcinoma by upregulating
thromspondin-1 expression. Anticancer Drugs. 21:381–388. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS
and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity
in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan Y, Zhou F, Zhang R and Claret FX:
Stat3 inhibitor Stattic exhibits potent antitumor activity and
induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Catanzaro D, Vianello C, Ragazzi E,
Caparrotta L and Montopoli M: Cell cycle control by natural phenols
in cisplatin-resistant cell lines. Nat Prod Commun. 9:1465–1468.
2014.PubMed/NCBI
|
|
16
|
Xie SM, Fang WY, Liu TF, Yao KT and Zhong
XY: Association of ABCC2 and CDDP-resistance in two sublines
resistant to CDDP derived from a human nasopharyngeal carcinoma
cell line. J Oncol. 2010:9150462010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
You Y, Liu J, Wang Z, Zhang Y, Ran Y, Guo
X, Liu H and Wang H: The enhancement of radio-sensitivity in human
esophageal squamous cell carcinoma cells by zoledronic acid and its
potential mechanism. Cytotechnology. 66:17–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koto K, Murata H, Kimura S, Horie N,
Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, et al:
Zoledronic acid inhibits proliferation of human fibrosarcoma cells
with induction of apoptosis, and shows combined effects with other
anticancer agents. Oncol Rep. 24:233–239. 2010.PubMed/NCBI
|
|
19
|
Zhao M, Tominaga Y, Ohuchida K, Mizumoto
K, Cui L, Kozono S, Fujita H, Maeyama R, Toma H and Tanaka M:
Significance of combination therapy of zoledronic acid and
gemcitabine on pancreatic cancer. Cancer Sci. 103:58–66. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan LH, Wang XT, Yang J, Kong FB, Lian C,
Wei WY, Luo W, Xie YB and Xiao Q: Reversal of multidrug resistance
in gastric cancer cells by E2F-1 downregulation in vitro and in
vivo. J Cell Biochem. 115:34–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Yang L, Zhang J, Zhang J, Chen Y,
Li K, Li Y, Li Y, Yao L and Guo G: Knock-down of NDRG2 sensitizes
cervical cancer Hela cells to cisplatin through suppressing Bcl-2
expression. BMC Cancer. 12:3702012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blagosklonny MV: Targeting cancer cells by
exploiting their resistance. Trends Mol Med. 9:307–312. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: An emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
25
|
Moriceau G, Ory B, Mitrofan L, Riganti C,
Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG,
et al: Zoledronic acid potentiates mTOR inhibition and abolishes
the resistance of osteosarcoma cells to RAD001 (Everolimus):
Pivotal role of the prenylation process. Cancer Res.
70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koizumi M, Nakaseko C, Ohwada C, Takeuchi
M, Ozawa S, Shimizu N, Cho R, Nishimura M and Saito Y: Zoledronate
has an antitumor effect and induces actin rearrangement in
dexamethasone-resistant myeloma cells. Eur J Haematol. 79:382–391.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li XY, Lin YC, Huang WL, Lin W, Wang HB,
Lin WZ and Lin SL: Zoledronic acid inhibits human nasopharyngeal
carcinoma cell proliferation by activating mitochondrial apoptotic
pathway. Med Oncol. 29:3374–3380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okuno S, Shimizu S, Ito T, Nomura M,
Hamada E, Tsujimoto Y and Matsuda H: Bcl-2 prevents
caspase-independent cell death. J Biol Chem. 273:34272–34277. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han T, Zhu X, Wang J, Zhao H, Ma Q, Zhao
J, Qiu X and Fan Q: Establishment and characterization of a
cisplatin-resistant human osteosarcoma cell line. Oncol Rep.
32:1133–1139. 2014.PubMed/NCBI
|
